← All indications
Pulmonary Fibrosis
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
Subtype terms (1)
More specific conditions that are subtypes of Pulmonary Fibrosis in the MeSH hierarchy.
- Idiopathic Pulmonary Fibrosis
185 drugs (66 approved, 119 experimental)
Drugs by status
Phase 4 trials (3)
Phase 3 trials (13)
Phase 2 trials (23)
Phase 1 trials (21)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (15)
- Actelion
- Roche
- Pfizer
- Cubist
- Boehringer Ingelheim
- University of London
- Indiana University
- Tel Aviv University
- University of California, Los Angeles
- University of Connecticut
- Icahn School of Medicine at Mount Sinai
- University of Lyon
- University of North Carolina at Chapel Hill
- Imperial College London
- Hartford Hospital
Organization Involved with Phase 3 Indications (54)
- Galapagos NV
- United Therapeutics
- Gilead Sciences
- Merck
- Genentech
- Zambon
- Novartis
- FibroGen
- Grupo Medifarma, S. A. de C. V.
- Neovii Biotech
- Fundación Pública Andaluza
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Pittsburgh
- Cornell University
- Harvard University
- Duke University
- Emory University
- Temple University
- University of Washington
- Indian Council of Medical Research
- Interstitial Lung Disease Study Group, Korea
- Katholieke Universiteit Leuven
- Johns Hopkins University
- Medical University of Gdansk
- Queen's University, Belfast
- Tata Memorial Hospital
- Tulane University
- University of Iowa
- University of Miami
- +24 more
Organization Involved with Phase 2 Indications (107)
- Kadmon
- Galecto Biotech
- Celgene
- Bristol-Myers Squibb
- MediciNova
- Debiopharm
- AstraZeneca
- Centocor
- MedImmune
- Sanofi
- Biogen
- Wyeth
- Arrowhead Pharmaceuticals
- Bayer
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Bharat Biotech International Limited
- Chiesi
- CoTherix
- Humanetics Corporation
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Lung Biotechnology PBC
- Nitto Denko Corporation
- Parexel
- Biosplice Therapeutics
- Promedior, Inc.
- ProMetic Life Sciences
- Reata Pharmaceuticals, Inc.
- Regend Therapeutics
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Trevi Therapeutics
- +77 more
Organization Involved with Phase 1 Indications (42)
- Theravance
- Genzyme
- Fosun
- Angion Biomedica Corp
- Aradigm Corporation
- GlaxoSmithKline
- ImmuneWorks
- Philips
- Sunshine Lake Pharma Co., Ltd.
- Toray Industries, Inc
- Zai Lab Pty. Ltd.
- The EMMES Corporation
- National Center for Research Resources (NCRR)
- Chinese Academy of Sciences
- Central South University
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Lakehead University
- Wake Forest University
- Assiut University
- Stony Brook University
- Celerion
- KCRN Research
- Covance
- Institute of Oncology Dr. Rosell (IOR)
- Instituto Nacional de la Nutrición Salvador Zubiran
- Clinica Universidad de Navarra
- University of Wisconsin
- University of Western Ontario
- University of Colorado
- Lester and Sue Smith Foundation
- +12 more
Organization Involved with Other Experimental Indications (20)
- Fundación Neumologica Colombiana
- National Cancer Institute (NCI)
- George Papanicolaou Hospital
- Henan University of Traditional Chinese Medicine
- South Valley University
- Thorax National Institute
- University of Seville
- University of South Florida
- University of Bern
- University of British Columbia
- The University of Hong Kong
- Henan Medical University
- Universidad Autonoma de Barcelona
- Sociedad Chilena de Enfermedades Respiratorias
- La Trobe University
- Government of Chile
- Institut Hospital del Mar d'Investigacions Mèdiques
- Universidad de la Sabana
- Stem Medicina Regenerativa
- CryoHoldco LATAM